| 2026-08-11 | Press release | PDF Version |
| 2026-08-11 | Press release | Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for th |
| 2026-08-05 | Deck | Corporate Presentation |
| 2026-08-05 | Press release | PDF Version |
| 2026-08-05 | Press release | Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-06-25 | Press release | Innoviva to Participate in the UBS Global Healthcare Conference |
| 2026-06-25 | Press release | Innoviva to Participate in the BofA Securities Health Care Conference |
| 2026-06-25 | Press release | Innoviva to Participate in the Cantor Global Healthcare Conference |
| 2026-06-23 | Press release | Innoviva Appoints Stephen Basso as Chief Financial Officer |
| 2026-06-23 | Press release | Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes |
| 2026-06-22 | Press release | Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference |
| 2026-06-22 | Press release | Innoviva Reports Second Quarter 2021 Financial Results |
| 2026-06-18 | Press release | Nortiva Bio Launches to Develop Long-Acting Oral Medicines |
| 2026-06-18 | Press release | Nortiva Bio Launches to Develop Long-Acting Oral Medicines |
| 2026-06-16 | Press release | Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets |
| 2026-06-16 | Press release | Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets |
| 2026-06-01 | Press release | Innoviva to Participate in Upcoming Investor Conferences |
| 2026-06-01 | Press release | Innoviva to Participate in Upcoming Investor Conferences |
| 2026-05-18 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-06 | Press release | Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress |
| 2026-05-06 | Press release | Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | 8-K | Form 8-K, Item 5.07 |
| 2026-03-27 | 10-K | Annual report on Form 10-K/A, FY25 |
| 2026-03-24 | Proxy | Definitive proxy statement |
| 2026-02-25 | Press release | Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress |
| 2026-02-25 | Press release | Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress |
| 2026-02-25 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-25 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-19 | Press release | Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-02-19 | Press release | Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2025-11-05 | Press release | Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-08-06 | Press release | Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress |
| 2025-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |